Key China COVID-19 examination delivered results that affected ensuing exploration on Covid Kumar Jeetendra | September 18, 2020 Crucial China COVID-19 study produced results that Affected subsequent research on coronavirus Early in the start of the COVID-19 pandemic, a small study in China produced results that affected subsequent research on the virus. Researchers at the University of Cincinnati used the same research parameters on a much larger patient population and reached completely different …
Study recommends e-cigarettes are adding to diminish smoking pervasiveness Kumar Jeetendra | September 19, 2020 Individuals who smoke are using e-cigarettes to try to give up smoking, a study by researchers at the University of Otago, Wellington, has discovered. The researchers found that between 2016 and 2018 the level of awareness, as well as the use of e-cigarettes, increased among smokers and those who had recently quit smoking. The principal …
Stage III preliminary of Oxford antibody to start in Pune one week from now Kumar Jeetendra | September 19, 2020 Pune, Sep 19 (PTI) The phase-III human clinical trial of the COVID-19 vaccine developed by Oxford University and being fabricated by the Serum Institute of India (SII) will begin at the Sassoon General Hospital in Pune next week. “The phase-III trial of”Covishield” vaccine will start in Sassoon hospital from next week. It’s likely to start …
New polygenic danger score to help foresee the chances of medications causing liver harm Kumar Jeetendra | September 20, 2020 The ancient Romans studied the livers of sacrificial animals to read omens and create prophesies. Researchers at Tokyo Medical and Dental University (TMDU) and Takeda-CiRA program alongside a world-wide group of collaborators, have devised a polygenic risk score (PRS) based on liver genomics that can predict the probability of medications causing liver damage. Adding new …
Chikungunya: The silent vector borne co-infection in Monsoon season Kumar Jeetendra | September 20, 2020 The prevalence of fever and joint pain is so common of symptoms that it overlaps with almost any prevalent disease in the tropics and hence for the better part of the virulent pathway of CHIK virus in the body, the patients remain asymptomatic to the detection of Chikungunya, thereby making it more life-threatening and requiring …
BDR Pharma to launch 80mg of Enzalutamide for treatment of Prostate Cancer in India Kumar Jeetendra | September 21, 2020 Mumbai 21st September 2020: BDR Pharmaceutical today announces the launch of 80mg advanced version of its Enzalutamide drug. BDR Pharma had earlier received approval from the Drugs Controller General of India (DCGI) to manufacture 40mg Enzalutamide in 2017 to treat men with metastatic castration-resistant prostate cancer (mCRPC) under the brand name BDENZA. The 80 mg …
Electronic Vaccine Intelligence Network to follow COVID-19 antibody Kumar Jeetendra | September 21, 2020 The Electronic Vaccine Intelligence Network (eVIN) system, which provides real-time information on vaccine stocks and storage temperatures across all cold chain points in the nation, has been enhanced to deal with the needs for distribution and tracking of COVID-19 vaccine, whenever it becomes available, the Rajya Sabha was informed on September 20. A national expert …
Oxford Covid-19 immunization: Serum Institute starts phase 3 of clinical preliminary Kumar Jeetendra | September 21, 2020 The phase-III or the last stage of clinical trial of the Covid-19 vaccine’Covishield’, being developed by Oxford University, also fabricated by the Serum Institute of India (SII), began today at the state-run Sassoon General Hospital in Pune, Maharashtra on Monday, a senior official said. “We have begun the phase-III trials of the vaccine candidate. We’ll …
Tests Show Outstanding Performance from Hydrophilic Vyon® Plastics Kumar Jeetendra | September 21, 2020 Porvair Sciences reports on testing that demonstrates how its hydrophilic Vyon® porous plastics exhibit outstanding performance in drug discovery applications due to the high hydrophilic void volume conversion of the materials’ pore structure after a special treatment process. Vyon® manufactured from HDPE (High Density Polyethylene) and & UHMWPE (Ultra-High Molecular Weight Polyethylene) is naturally hydrophobic …
Flu antibody doesn’t expand COVID-19 danger: Study Kumar Jeetendra | September 22, 2020 Receiving the influenza vaccine does not increase a person’s risk for contracting COVID-19 or aggravate related conditions or mortality, according to a study. The study, published in the Journal of Clinical and Translational Science, shows the flu vaccine is the single most important intervention to help stay healthy. Seasonal flu activity is unpredictable, and healthy …
Russia to enlist second COVID-19 antibody by October 15 Kumar Jeetendra | September 22, 2020 Russia expects to register a second possible vaccine against COVID-19 from October 15, the TASS news agency mentioned Russian consumer security watchdog Rospotrebnadzor as saying on Tuesday. The vaccine was developed by Siberia’s Vector Institute, which completed early-stage human trials of the vaccine last week. Russia registered its first vaccine candidate, developed by Moscow’s Gamaleya …
India preliminaries for Russia’s ‘Sputnik-V’ antibody may start in next barely any weeks: Dr Reddy’s Kumar Jeetendra | September 22, 2020 Reddy’s Laboratories Ltd could start late-stage Indian clinical trials of Russia’s potential coronavirus vaccine within the next few months, an executive in the Indian drugmaker said on Tuesday. Indian trials of this Sputnik-V vaccine candidate, being developed by Russia’s sovereign wealth fund, will enroll 1,000-2,000 participants and also be conducted at multiple private and government …
